- Marketwired•15 hours ago
GeoVax Labs, Inc. , a biotechnology company specializing in developing human vaccines, announced today the presentation of clinical data from a phase 1 human clinical trial of its investigational HIV vaccine ...
- Marketwired•18 days agoGeoVax to Present at Upcoming Scientific Conferences on Its Hemorrhagic Fever and Zika Vaccine Programs
GeoVax Labs, Inc. , a biotechnology company specializing in developing human vaccines, announced today that its Senior Vice President of Research and Development, Dr. Farshad Guirakhoo, will present at ...
- Zacks Small Cap Research•2 months ago
By Grant Zeng, CFA OTC:GOVX Update on Second Quarter Financials Total revenue was $166,280 for the three-month ended June 30, 2016, related to grants from the NIH in support of its HIV/AIDS vaccine development ...
GeoVax Labs, Inc. (GOVX)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.08 - 0.08|
|52wk Range||0.05 - 0.14|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.86|
|Avg Vol (3m)||402,244|
|Dividend & Yield||N/A (N/A)|